PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer.
gastroenterology
immunology
tumours
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
accepted:
29
06
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
8
9
2021
Statut:
ppublish
Résumé
Overexpression of programmed cell death protein 1 (PD-1) is linked to CD8+ T cell dysfunction and contributes to tumor immune escape. However, the prevalence and functional regulations of PD-1 expression on CD8+ T cells in human gastric cancer (GC) remain largely unknown. Flow cytometry was performed to analyze the level, phenotype, functional and clinical relevance of PD-1+CD8+ T cells in GC patients. Peripheral blood CD8+ T cells were purified and subsequently exposed to culture supernatants from digested primary GC tumor tissues (TSN) in vitro for PD-1 expression and functional assays. Tumor responses to adoptively transferred TSN-stimulated CD8+ T cells or to the TSN-stimulated CD8+ T cell transfer combined with an anti-PD-1 antibody injection were measured in an in vivo xenograft mouse model. GC patients' tumors showed a significantly increased PD-1+CD8+ T cell infiltration. However, these GC-infiltrating PD-1+CD8+ T cells showed equivalent function to their PD-1-CD8+ counterparts and they did not predict tumor progression. High level of transforming growth factor-β1 (TGF-β1) in tumors was positively correlated with PD-1+CD8+ T cell infiltration, and in vitro GC-derived TGF-β1 induced PD-1 expression on CD8+ T cells via Smad3 signaling, whereas Smad2 signaling was involved in GC-derived TGF-β1-mediated CD8+ T cell dysfunction. Furthermore, GC-derived TGF-β1-mediated CD8+ T cell dysfunction contributed to tumor growth in vivo that could not be attenuated by PD-1 blockade. Our data highlight that GC-derived TGF-β1 promotes PD-1 independent CD8+ T cell dysfunction. Therefore, restoring CD8+ T cell function by a combinational PD-1 and TGF-β1 blockade might benefit future GC immunotherapy.
Sections du résumé
BACKGROUND
Overexpression of programmed cell death protein 1 (PD-1) is linked to CD8+ T cell dysfunction and contributes to tumor immune escape. However, the prevalence and functional regulations of PD-1 expression on CD8+ T cells in human gastric cancer (GC) remain largely unknown.
METHODS
Flow cytometry was performed to analyze the level, phenotype, functional and clinical relevance of PD-1+CD8+ T cells in GC patients. Peripheral blood CD8+ T cells were purified and subsequently exposed to culture supernatants from digested primary GC tumor tissues (TSN) in vitro for PD-1 expression and functional assays. Tumor responses to adoptively transferred TSN-stimulated CD8+ T cells or to the TSN-stimulated CD8+ T cell transfer combined with an anti-PD-1 antibody injection were measured in an in vivo xenograft mouse model.
RESULTS
GC patients' tumors showed a significantly increased PD-1+CD8+ T cell infiltration. However, these GC-infiltrating PD-1+CD8+ T cells showed equivalent function to their PD-1-CD8+ counterparts and they did not predict tumor progression. High level of transforming growth factor-β1 (TGF-β1) in tumors was positively correlated with PD-1+CD8+ T cell infiltration, and in vitro GC-derived TGF-β1 induced PD-1 expression on CD8+ T cells via Smad3 signaling, whereas Smad2 signaling was involved in GC-derived TGF-β1-mediated CD8+ T cell dysfunction. Furthermore, GC-derived TGF-β1-mediated CD8+ T cell dysfunction contributed to tumor growth in vivo that could not be attenuated by PD-1 blockade.
CONCLUSIONS
Our data highlight that GC-derived TGF-β1 promotes PD-1 independent CD8+ T cell dysfunction. Therefore, restoring CD8+ T cell function by a combinational PD-1 and TGF-β1 blockade might benefit future GC immunotherapy.
Identifiants
pubmed: 32753468
pii: jitc-2019-000422
doi: 10.1136/jitc-2019-000422
pmc: PMC7406116
pii:
doi:
Substances chimiques
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Br J Cancer. 2008 Nov 18;99(10):1704-11
pubmed: 18941457
Cancer Cell. 2005 Nov;8(5):369-80
pubmed: 16286245
Oncoimmunology. 2016 Nov 8;5(12):e1254855
pubmed: 28123898
Nat Med. 2018 Sep;24(9):1449-1458
pubmed: 30013197
Anticancer Res. 2019 Jan;39(1):443-448
pubmed: 30591493
J Exp Med. 2010 Sep 27;207(10):2175-86
pubmed: 20819923
Gut. 2017 Nov;66(11):1900-1911
pubmed: 28274999
Cancer Res. 2012 Feb 15;72(4):887-96
pubmed: 22205715
J Invest Dermatol. 2011 Jun;131(6):1300-7
pubmed: 21346771
Oncoimmunology. 2015 Feb 25;4(4):e998538
pubmed: 26137416
Br J Cancer. 2014 Sep 23;111(7):1391-9
pubmed: 25093496
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Annu Rev Med. 2018 Jan 29;69:301-318
pubmed: 29414259
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
J Immunol. 2017 Feb 15;198(4):1729-1739
pubmed: 28053236
Nat Med. 2015 May;21(5):449-56
pubmed: 25894828
Front Immunol. 2013 Dec 19;4:455
pubmed: 24391639
Cancer Immunol Res. 2015 Dec;3(12):1344-55
pubmed: 26253731
Crit Rev Oncol Hematol. 2019 Jan;133:25-32
pubmed: 30661655
Cancer Discov. 2016 Dec;6(12):1366-1381
pubmed: 27683557
Cell Metab. 2019 Jul 2;30(1):143-156.e5
pubmed: 31031094
J Clin Invest. 2011 Jun;121(6):2350-60
pubmed: 21555851
J Surg Oncol. 2013 Apr;107(5):517-22
pubmed: 23129549
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Cancer Res. 2017 Feb 15;77(4):851-861
pubmed: 27979840
Gastroenterology. 2018 Dec;155(6):1936-1950.e17
pubmed: 30145359
Nat Commun. 2018 Oct 16;9(1):4297
pubmed: 30327458
Cancer Immunol Res. 2017 Mar;5(3):248-256
pubmed: 28148545
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
Cancer Immunol Res. 2019 May;7(5):737-750
pubmed: 30842092
J Clin Oncol. 2010 Sep 10;28(26):4045-51
pubmed: 20644090
J Immunother Cancer. 2018 Jun 4;6(1):47
pubmed: 29866156
PLoS Pathog. 2014 Sep 25;10(9):e1004380
pubmed: 25255144
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
Annu Rev Immunol. 2006;24:99-146
pubmed: 16551245
Lancet. 2018 Jul 14;392(10142):123-133
pubmed: 29880231
Eur J Immunol. 2008 Oct;38(10):2886-95
pubmed: 18825745
J Immunol Res. 2016;2016:8941260
pubmed: 27314056